Introduction: Osimertinib is a third-generation EGFRtyrosine kinase inhibitor (TKI). Durvalumab is an antiprogrammed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy.
Methods: Patients were randomly assigned 1:1 to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks) until progression. Treatment could continue beyond progression, providing clinical benefit continued (judged by the investigator). The amended primary objective was to assess the safety and tolerability of osimertinib plus durvalumab; efficacy was an exploratory objective.
Results: CAURAL recruitment was terminated early because of increased incidence of interstitial lung diseaselike events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466). At termination of CAURAL recruitment, 15 patients had been randomly assigned to treatment with osimertinib and 14 to treatment with osimertinib plus durvalumab. The most common AEs were diarrhea (53% [grade 3 in 6% of patients]) in the osimertinib arm and rash (67% [grade 3 in 0 patients]) in the combination arm. One patient who had been randomized to the combination arm reported grade 2 interstitial lung disease while receiving osimertinib monotherapy (after discontinuing durvalumab therapy after one dose). The objective response rates were 80% in the osimertinib arm and 64% in the combination arm.
Conclusion: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms. The combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
Introduction
Mutations in the EGFR gene are observed in approximately 40% and 20% of patients with NSCLC in Asian and non-Asian populations, respectively. 1 Osimertinib, a third-generation, central nervous system-active, irreversible EGFR-tyrosine kinase inhibitor (TKI), is selective for both EGFR-TKI sensitizing mutations (EGFRm) and EGFR T790M resistance mutations. 2, 3 Osimertinib is a treatment option for patients with advanced NSCLC harboring EGFRm in the first-line setting and the treatment of choice for patients with T790M-positive NSCLC after disease progression during treatment with a firstline EGFR-TKI. 2, 3 Durvalumab, a selective, high-affinity, engineered human immunoglobulin G1 monoclonal antibody, blocks binding of programmed cell death 1 ligand 1 (PD-L1) to programmed cell death protein 1 (PD-1) and CD80 molecule. 4 Murine models have demonstrated significant response to anti-PD-1 antibody treatment in EGFRmutant tumors. 5 EGFR activation has been shown to induce PD-L1 expression; therefore, EGFR-TKIs may enhance antitumor immunity through downregulation of PD-L1. 5, 6 The phase III, open-label, randomized CAURAL trial (NCT02454933) was planned to investigate osimertinib plus durvalumab versus osimertinib monotherapy in patients with T790M-positive advanced NSCLC and disease progression after EGFR-TKI therapy.
CAURAL recruitment terminated early after the interim safety results from a phase 1b study of osimertinib plus durvalumab for EGFRm NSCLC (TATTON [NCT02143466]), which observed a higher than expected incidence of interstitial lung disease (ILD)-like events (13 of 34 patients [38%]), none of which were fatal. 7 We present CAURAL safety and efficacy results.
Methods

Patients
Eligible patients were aged 18 years or older (in Japan, 20 years) and had a WHO performance status of 0 or 1 and EGFRm locally advanced/metastatic NSCLC (stage IIIB-IV). Radiological documentation of disease progression after EGFR-TKI therapy was mandatory; other lines of therapy also may have been given. Centrally confirmed T790M-positive tumor status from a biopsy sample taken after disease progression during the most recent therapy was required. Patients with stable, asymptomatic, central nervous system metastases were eligible. Patients with a history or evidence of clinically active ILD or radiation pneumonitis were ineligible.
Trial Design and Treatment
Patients were randomized centrally (1:1) to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks). The stratification factors were previous lines of treatment (one versus two or more), and ethnicity (Asian versus non-Asian). Treatment could continue beyond disease progression, provided clinical benefit continued (judged by the investigator).
Objectives
The amended primary objective was assessment of safety and tolerability of osimertinib plus durvalumab. Exploratory objectives included the safety of osimertinib and efficacy of osimertinib monotherapy and combination therapy.
Outcome Measures
Safety and tolerability outcome measures included adverse events (AEs) graded by the Common Terminology Criteria for Adverse Events, version 4. The efficacy outcome measures included investigator-assessed (according to the Response Evaluation Criteria in Solid Tumors, version 1.1) objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), tumor shrinkage, disease control rate, and overall survival (OS).
Statistical Analysis
Safety data were summarized according to randomized treatment received in the safety analysis set (patients who received at least one dose). Efficacy data were summarized according to randomized treatment in the full analysis set (all randomized patients regardless of treatment received). At time of recruitment termination, the sample size was too small for formal statistical comparisons between arms; summaries are descriptive. PFS, DoR, and OS were summarized by using KaplanMeier estimates. ORR was summarized with associated 95% confidence intervals (CIs) by using the ClopperPearson method. The data cutoff (DCO) date was March 21, 2018. These are the final data to be reported from this study.
Trial Oversight
The trial was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, applicable regulatory requirements, and policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca. The trial was funded by the sponsor and designed by the principal investigators and sponsor.
Results
Patients and Treatment
A total of 29 patients from nine centers in South Korea, Canada, and the Republic of China (Taiwan) were randomized: 15 to osimertinib monotherapy and 14 to osimertinib plus durvalumab combination therapy (Table 1 and Fig. 1 ). Two patients were incorrectly randomized to combination therapy, switched to osimertinib therapy, and never received durvalumab.
All 12 patients who received durvalumab stopped taking it during the study owing to disease progression (n ¼ 5), AE (n ¼ 3 [with two of these cases possibly causally related]), patient withdrawal (n ¼ 3), or investigator decision (n ¼ 1). The median duration of durvalumab treatment was 10.0 months (range 0-27 months). In all, 22 patients (76%) (12 of whom received osimertinib alone and 10 of whom received combination therapy) discontinued osimertinib during the study because of disease progression (n ¼ 17), an AE (n ¼ 2), or patient withdrawal (n ¼ 3). Seven patients (24%) (five who were receiving osimertinib and two who were receiving combination therapy) were still receiving osimertinib at DCO. The median duration of osimertinib treatment was 21.1 months overall (range 2-30 months), and the median durations of treatment were 23.9 and 17.1 months in the osimertinib and combination arms, respectively (Fig. 2) .
Safety
Overall, all patients in the safety analysis set (17 patients who received osimertinib monotherapy and 12 who received combination therapy) had at least one AE (mostly grade 1 or 2) (Tables 2 and 3 ). The most commonly reported AEs, regardless of causality and severity, were diarrhea (n ¼ 9 [53%]), rash (n ¼ 9 [53%]), and paronychia (n ¼ 7 [41%]) in the osimertinib arm and rash (n ¼ 8 [67%]), diarrhea (n ¼ 6 [50%]), and decreased appetite (n ¼ 6 [50%]) in the combination arm.
Only one patient (3%) (who was randomized to combination therapy) had ILD reported (grade 2). The patient discontinued durvalumab therapy (consent withdrawal) on day 1 after one dose; the event was reported on day 63 while the patient was receiving osimertinib. The investigator reported it as a serious AE (because of hospitalization) that was possibly causally related to osimertinib and unrelated to durvalumab. The study treatment was discontinued permanently in response. The event was reported as resolving at time of death due to disease progression (113 days after the last osimertinib dose).
In all, 10 patients had an AE of grade 3 or higher a Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories. Includes adverse events with an onset date on or after the date of first dose of study treatment and up to and including 30 days after the date of last dose of osimertinib or 90 days after the last dose of durvalumab, whichever is later. AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious adverse event. 4 -not calculable) in the combination arm. The disease control rate was 100% (95% CI: 78-100) in the osimertinib arm versus 93% (95% CI: 66-100) in the combination arm. All patients had a reduction in target lesion size compared with baseline (Fig. 3) .
Confirmed (according to the Response Evaluation Criteria in Solid Tumors) progression was documented in four of 15 patients (27%) in the osimertinib arm and four of 14 (29%) in the combination arm. The median PFS was 19.3 months in the osimertinib arm versus not reached in the combination arm. The 12-month progression-free rates were 82% and 76%, respectively.
At DCO, two of 15 patients (13%) in the osimertinib arm and four of 14 patients (29%) in the combination arm had died. The median OS was not reached in either arm; the 12-month survival rate was 100% for the osimertinib arm versus 86% (95% CI: 54-96) for the combination arm.
Discussion
As limited patients were randomized, formal safety and efficacy comparisons between treatment arms were not possible. However, we observed no trends suggesting the combination therapy to be superior to osimertinib alone; the response to osimertinib monotherapy was consistent with the existing efficacy profile seen in phase II/III trials of osimertinib in patients with T790M-positive advanced NSCLC. 8, 9 There were no new safety signals for osimertinib in combination with durvalumab or as monotherapy.
A meta-analysis of first-generation EGFR-TKI monotherapy (gefitinib/erlotinib) studies reported an ILD incidence at 1.2% (95% CI: 0.9-1.6%), ranging from 0% to 5%. 10 The incidence of ILD with osimertinib is in line with that for first-generation EGFR-TKIs, with rates of 2% to 4% in large phase II/III trials. 8, 9, 11 An unexpectedly high incidence of ILD-like events (in 13 of 34 patients [38%]) was reported in the osimertinib plus durvalumab arm of TATTON. 7 In CAURAL, only one ILD event was reported in 12 patients who received 
